Literature DB >> 17268513

Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.

A Matsuda1, U Germing, I Jinnai, M Iwanaga, M Misumi, A Kuendgen, C Strupp, Y Miyazaki, H Tsushima, M Sakai, M Bessho, N Gattermann, C Aul, M Tomonaga.   

Abstract

In the criteria of refractory cytopenia with multilineage dysplasia (RCMD) according to the WHO (World Health Organization) classification, the frequency threshold concerning dysplasia of each lineage was defined as 10%. To predict overall survival (OS) and leukemia-free survival (LFS) for patients with refractory anemia (RA) according to the French-American-British (FAB) classification, we investigated prognostic factors based on the morphological features of 100 Japanese and 87 German FAB-RA patients, excluding 5q-syndrome. In the univariate analysis of all patients, pseudo-Pelger-Huet anomalies >or=10% (Pelger+), micromegakaryocytes >or=10% (mMgk+), dysgranulopoiesis (dys G) >or=10% and dysmegakaryopoiesis (dys Mgk) >or=40% were unfavorable prognostic factors for OS and LFS (OS; P<0.001, LFS; P<0.001). The prognostic effects of the morphological features were similar in both Japanese and German patients. However, dys Mgk >or=10% was not correlated with OS and LFS. In the multivariate analysis, mMgk+ and dys Mgk>or=40% were adverse prognostic factors for OS for all patients, and dys G >or=10% and dys Mgk>or=40% were adverse prognostic factors for LFS for all patients. On the basis of the present analysis, we propose the following modified morphological criteria for RCMD. Modified RCMD should be defined as FAB-RA, excluding 5q-syndrome with dys G >or=10%, dys Mgk>or=40% or mMgk+.

Entities:  

Mesh:

Year:  2007        PMID: 17268513     DOI: 10.1038/sj.leu.2404571

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors.

Authors:  Stefani Parmentier; Johannes Schetelig; Kerstin Lorenz; Michael Kramer; Robin Ireland; Ulrich Schuler; Rainer Ordemann; Gabi Rall; Markus Schaich; Martin Bornhäuser; Gerhard Ehninger; Frank Kroschinsky
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.

Authors:  Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 3.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

4.  Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization.

Authors:  Chun-Mei Fu; Zi-Xing Chen; Dan-Dan Liu; Jun Zhang; Jin-Lan Pan; Jian-Ying Liang
Journal:  Int J Hematol       Date:  2014-11-28       Impact factor: 2.490

5.  Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.

Authors:  Raphael Itzykson; Thomas Cluzeau; Matthieu Duchmann; Orianne Wagner-Ballon; Thomas Boyer; Meyling Cheok; Elise Fournier; Estelle Guerin; Laurène Fenwarth; Bouchra Badaoui; Nicolas Freynet; Emmanuel Benayoun; Daniel Lusina; Isabel Garcia; Claude Gardin; Pierre Fenaux; Cécile Pautas; Bruno Quesnel; Pascal Turlure; Christine Terré; Xavier Thomas; Juliette Lambert; Aline Renneville; Claude Preudhomme; Hervé Dombret
Journal:  Leukemia       Date:  2021-10-06       Impact factor: 11.528

6.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

7.  Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Authors:  Leonor Senent; Leonor Arenillas; Elisa Luño; Juan C Ruiz; Guillermo Sanz; Lourdes Florensa
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes.

Authors:  Nobutaka Kawai; Akira Matsuda; Itsuro Jinnai; Takaya Ichimura; Hidekazu Kayano; Daisuke Okamura; Maho Ishikawa; Tomoya Maeda; Tomoko Hata; Yasushi Miyazaki; Norio Asou; Masami Bessho; Masao Tomonaga
Journal:  Int J Hematol       Date:  2015-11-25       Impact factor: 2.490

9.  Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues.

Authors:  Geetanjali Gupta; Reecha Singh; Dhananjay S Kotasthane; Vaishali D Kotasthane
Journal:  J Blood Med       Date:  2010-08-25

Review 10.  Importance of classical morphology in the diagnosis of myelodysplastic syndrome.

Authors:  Rosangela Invernizzi; Federica Quaglia; Matteo Giovanni Della Porta
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.